miércoles, 30 de octubre de 2019

Data falsification: still a problem in drug plants in India and China - STAT

Data falsification: still a problem in drug plants in India and China - STAT

Daily Recap

Opinion: In generic drug plants in China and India, data falsification is still a problem

By KATHERINE EBAN AND SONY SALZMAN


RAFIQ MAQBOOL/AP
The FDA touted approving more than 1,000 generic drugs in fiscal 2019. That's not good news if Indian and Chinese plants are manipulating FDA-required data.

No hay comentarios:

Publicar un comentario